阿托伐他汀治疗早期糖尿病肾病临床疗效观察

目的观察阿托伐他汀对糖尿病肾病（DN）患者的肾脏的保护作用。方法将86例DN患者随机分为两组,两组患者均给予糖尿病饮食、控制血糖和降血压等常规治疗,对照组给予贝那普利,观察组在对照组治疗的基础上给予阿托伐他汀,两组疗程均为12周。于治疗前和治疗12周后检测两组尿微量白蛋白排泄率（UAER）、血肌酐（Scr）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、甘油三酯（TG）、空腹血糖（FPG）、糖化血红蛋白（HbA1c）。结果治疗后与治疗前比较,对照组UAER、TC、FBG、HbA1c显著降低（P〈0.05）,治疗组UAER、Scr、LDL-C、TC、TG、FBG、HbA1c显著降低（P〈0.05）;两组治疗后比较,治疗组UAER、Scr、TC、TG显著低于对照组（P〈0.05）。结论阿托伐他汀可以减少蛋白尿,延缓肾功能的恶化。

Atorvastatin for the Treatment of Early Diabetic Nephropathy: Clinical Observation

Objective To observe protection of atorvastatin on kidney in patients with early diabetic nephropathy.Methods 86 patients with diabetic nephropathy were randomly divided into two groups.The routine treatment included administration of diabetic diet,blood glucose control and lossing blood pressure for 8 weeks.Benazepril was performed in control group for 8 weeks.Urinary albumin excretion rate（UAER）,serum creatinine（Scr）,low density lipoprotein-C（LDL-C）,total cholesterol（TC）,triglyceride（TG）,fasting plasma glucose（FPG）,and glycosylated hemoglobin（HbA1C） were detected and compared before treatment and 12 weeks later in two groups.Results Levels of UAER,TC,FBG,HbA1c decreased obviously in control group（P0.05）.Levels of UAER,Scr,LDL-C,TC,TG,FBG,HbA1c decreased obviously in treatment group（P0.05）.Levels of UAER,Scr,TC,TG of treatment group were obviously lower than those of control group（P0.05）.Conclusion Combination of atorvastatin and benazepril can decrease UAER and improve renal function.